MMR/MSI in endometrial cancer
5 EU-approved indications in endometrial cancer need a MMR/MSI result: pembrolizumab (advanced), dostarlimab (2nd line, advanced), durvalumab (maintenance, advanced), durvalumab (maintenance, advanced) and olaparib (maintenance, advanced).
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| dMMR / MSI-H3 | ||||
Imfinzi | Mismatch repair deficient (dMMR) | Monotherapy | Maint. advanced | After first-line durvalumab + carboplatin and paclitaxel without progression; Candidates for systemic therapy |
Jemperli | Monotherapy | 2L advanced | Progressed on or following prior treatment with a platinum-containing regimen | |
Keytruda | Monotherapy | Any line advanced | Disease progression on or following prior treatment with a platinum-containing therapy in any setting; Not candidates for curative surgery or radiation | |
| pMMR / MSS2 | ||||
Imfinzi | Mismatch repair proficient (pMMR) | + olaparib | Maint. advanced | After first-line durvalumab + carboplatin and paclitaxel without progression; Candidates for systemic therapy |
Lynparza | Mismatch repair proficient | + durvalumab | Maint. advanced | After first-line treatment with durvalumab in combination with carboplatin and paclitaxel without progression |
5 approvals for Endometrial need no biomarker and apply whatever the result. All approvals for Endometrial
See also
Label wording5
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Pembrolizumab (Keytruda)
advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation;
- Dostarlimab (Jemperli)
JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.
- Durvalumab (Imfinzi)
IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
- Durvalumab (Imfinzi)
IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
- Olaparib (Lynparza)
Lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.